Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
5.02
+0.35 (7.49%)
Oct 4, 2024, 4:00 PM EDT - Market closed
Molecular Partners AG Employees
Molecular Partners AG had 168 employees as of December 31, 2023. The number of employees decreased by 8 or -4.45% compared to the previous year.
Employees
168
Change (1Y)
-8
Growth (1Y)
-4.45%
Revenue / Employee
$52,234
Profits / Employee
-$382,858
Market Cap
159.81M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
The Joint | 794 |
Lifecore Biomedical | 524 |
biote | 194 |
Generation Bio Co. | 174 |
Caribou Biosciences | 158 |
ProQR Therapeutics | 157 |
BrainsWay | 134 |
Alpha Tau Medical | 121 |
MOLN News
- 1 day ago - Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting - GlobeNewsWire
- 8 days ago - Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 - GlobeNewsWire
- 5 weeks ago - Molecular Partners Reports H1 2024 Corporate Highlights and Financials - GlobeNewsWire
- 2 months ago - Molecular Partners: A Speculative Bet On Innovative DARPin Technology - Seeking Alpha
- 3 months ago - Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit - GlobeNewsWire
- 4 months ago - Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 - GlobeNewsWire
- 4 months ago - Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 - GlobeNewsWire
- 4 months ago - Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 - GlobeNewsWire